GENETICS Presents AI-Driven Patient Stratification Research For NSCLC Immunotherapy At ESMO 2024
GENETICS Presents AI-Driven Patient Stratification Research For NSCLC Immunotherapy At ESMO 2024
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy
研究強調利用多模態機器學習來確定非小細胞肺癌患者，預測其從聯合免疫療法中獲益最大
BOSTON and ROLLE, Switzerland, Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy.
2024年9月14日，波士頓和瑞士羅勒/ PRNewswire/ - SOPHiA GENETICS（NASDAQ：SOPH）是一家雲原生醫療技術公司和數據驅動醫學領域的領導者。該公司將在2024年歐洲醫學腫瘤學會（ESMO）上公開新的研究。這項與阿斯利康合作的研究利用先進的AI驅動技術來識別IV期非小細胞肺癌（NSCLC）患者的亞群，這些患者在加入tremelimumab到durvalumab和化療方案中最有益。
譯文內容由第三人軟體翻譯。